An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects
Completed
AbbVie
Phase 2
2014-01-24
This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is
to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on
immunological responses to Prevnar 13® in RA patients.
A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone
Completed
AbbVie
Phase 2
2014-03-26
The primary objective of the study was to compare the safety and efficacy of multiple doses
of upadacitinib versus placebo in adults with moderately to severely active rheumatoid
arthritis (RA) on stable background methotrexate therapy who had not shown an adequate
response to methotrexate alone.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intoleran
Completed
AbbVie
Phase 2
2015-03-17
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately
to severely active Crohn's Disease with a history of inadequate response to or intolerance to
Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
Active, not recruiting
AbbVie
Phase 3
2015-12-01
The purpose of this study was to assess efficacy, including inhibition of radiographic
progression, and safety with upadacitinib versus placebo and versus an active comparator,
adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who
are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
